A team of scientists led by the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School (Duke-NUS) has found a new approach for treating some of the world’s most aggressive cancers associated with BAP1 mutations. Their research, published in the journal Science Translational Medicine on 1 April 2026, uncovers how BAP1 functions at the molecular level and presents a novel therapeutic strategy to slow the progression of mesothelioma, uveal melanoma, cholangiocarcinoma, and clear cell renal cell carcinoma harboring BAP1 mutations.
This article was originally published on MedicalXpress.com
